DUBLIN--(BUSINESS WIRE)--The "Monoamine Oxidase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "Monoamine Oxidase Inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Monoamine Oxidase Inhibitors pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Monoamine Oxidase Inhibitors Emerging Drugs Chapters
This segment of the Monoamine Oxidase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Monoamine Oxidase Inhibitors Emerging Drugs
Ladostigil: Avraham Pharmaceuticals
Ladostigil (TV-3,326) is a novel neuroprotective agent being investigated for the treatment of neurodegenerative disorders like Alzheimer's disease, Lewy body disease, and Parkinson's disease.
It acts as a reversible acetylcholinesterase andbutyrylcholinesterase inhibitor, and an irreversible monoamine oxidase B inhibitor, and combines the mechanisms of action of older drugs like rivastigmine and rasagiline into a single molecule.
In addition to its neuroprotective properties, ladostigil enhances the expression of neurotrophic factors like GDNF and BDNF, and may be capable of reversing some of the damage seen in neurodegenerative diseases via the induction of neurogenesis. Ladostigil also has antidepressant effects, and may be useful for treating comorbid depression and anxiety often seen in such diseases as well.
Safinamide: Newron Pharmaceuticals
A selective monoamine oxidase B (MAO-B) inhibitor, which reduces the degradation of secreted dopamine, helping to maintain the density of dopamine in the brain. The drug is in phase 2 stage of development for the treatment of Drug-induced dyskinesia.
Monoamine Oxidase Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Monoamine Oxidase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on Monoamine Oxidase Inhibitors
There are approx. 7+ key companies which are developing the Monoamine Oxidase Inhibitors. The companies which have their Monoamine Oxidase Inhibitors drug candidates in the most advanced stage, i.e. preregistration include, Amgen.
This report covers around 7+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Monoamine Oxidase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Monoamine Oxidase Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Monoamine Oxidase Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Monoamine Oxidase Inhibitors drugs.
The companies and academics are working to assess challenges and seek opportunities that could influence Monoamine Oxidase Inhibitors R&D. The therapies under development are focused on novel approaches for Monoamine Oxidase Inhibitors.
Monoamine Oxidase Inhibitors Report Insights
- Monoamine Oxidase Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Monoamine Oxidase Inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Scenario and Emerging Therapies:
- How many companies are developing Monoamine Oxidase Inhibitors drugs?
- How many Monoamine Oxidase Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Monoamine Oxidase Inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Monoamine Oxidase Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Monoamine Oxidase Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Avraham Pharmaceuticals
- PREXA SANTE
- Newron Pharmaceuticals
- Oryzon Genomics
- Changzhou Si Yao Pharmaceutical
- Methylthioninium chloride
- BN 82451
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ac9yrh